Results 151 to 160 of about 931,716 (345)

Understanding excess body weight: New Zealand Health Survey [PDF]

, 2015
Explores the increase in obesity over a 36 year period to 2013 and investigates the impact of obesity on different birth cohorts. Summary Obesity is New Zealand’s leading modifiable risk factor for health loss.
Hilary Sharpe, Sarah Bradbury
core  

Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1474-1478, April 2025.
Abstract Aims ZSF1 obese rats harbouring two mutant leptin receptor alleles (Leprcp and Leprfa) develop metabolic syndrome and heart failure with preserved ejection fraction (HFpEF), making them a widely used animal model in cardiometabolic research.
Petra Büttner, Antje Augstein, Mahmoud Abdellatif, André Lourenço, Adelino Leite‐Moreira, Inês Falcão‐Pires, Sarah Werner, Holger Thiele, Simon Sedej, Antje Schauer, Volker Adams   +10 more
wiley   +1 more source

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlström, Stephan Rosenkranz, Francesco Cosentino, Giuseppe M.C. Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H. Lund, Gianluigi Savarese   +12 more
wiley   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Resolution of Pseudotumor Cerebri following surgery for morbid obesity

, 2010
The cause of pseudotumor cerebri (PTC) is poorly understood although there is strong evidence that obesity plays a role in its development. This report describes a patient with medically intractable PTC, who had continued symptoms despite undergoing a ...
JDT Morgan, A Williams, SA Norton, AB Johnson, I Pople, SE Bates   +5 more
core  

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Improved Physical, Emotional, and Social Well-Being in People Living With Obesity Treated With Semaglutide: A Plain Language Summary

Therapeutic Advances in Endocrinology and Metabolism
Summary What is this summary about? Many people live with extra weight or obesity. Semaglutide is a type of weight loss medication for the treatment of obesity. A study published in 2024 reported on the experiences of people taking semaglutide.
Ronette L. Kolotkin, Rajitha K., Henrik Brandi, Julie Hviid Hahn-Pedersen   +3 more
doaj   +1 more source

Obesity and Skill Attainment in Early Childhood [PDF]

This paper investigates the association between obesity and skill attainment in early childhood (aged 2-4 years). Data from the German Socio-Economic Panel Study are used to estimate models of developmental functioning in four critical areas (verbal ...
John Cawley, C. Katharina Spiess
core  

Histopatologia gástrica na gastrectomia vertical laparoscópica : comparação pré e pós-operatória [PDF]

, 2013
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-Graduação em Ciências Médicas , Florianópolis, 2013Introdução: A obesidade mórbida é uma doença multifatorial com diversas implicações clínicas ...
Onzi, Tiago Rafael
core